Dr. med.
Cornelia Schroeder
  • Wissenschaftliche Mitarbeiterin
  • Fachärztin
  • Fachärztin für Viszeralchirurgie
Arbeitsbereich

Standort

Hauptgebäude O10 , 2. Etage
Sprachen
Deutsch (Muttersprache)

Fachgebiete

Tätigkeitsschwerpunkte

Publikationen

Zurück
  • 2020
  • 2019
  • 2018
  • 2017
  • 2012
Vor

Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer
Höflmayer D, Steinhoff A, Hube-Magg C, Kluth M, Simon R, Burandt E, Tsourlakis M, Minner S, Sauter G, Büscheck F, Wilczak W, Steurer S, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C
MOL ONCOL. 2020;14(1):129-138.

Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers
Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis M, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C
PROSTATE. 2019;79(3):302-311.

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer
Schroeder C, Grell J, Hube-Magg C, Kluth M, Lang D, Simon R, Höflmayer D, Minner S, Burandt E, Clauditz T, Büscheck F, Jacobsen F, Huland H, Graefen M, Schlomm T, Sauter G, Steurer S
BMC CANCER. 2019;19(1):193.

Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy
Schroeder C, Navid-Hill E, Meiners J, Hube-Magg C, Kluth M, Makrypidi-Fraune G, Simon R, Büscheck F, Luebke A, Goebel C, Lang D, Weidemann S, Neubauer E, Hinsch A, Jacobsen F, Lebok P, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Sauter G, Höflmayer D
ONCOTARGET. 2019;10(48):4973-4986.

Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion
Steurer S, Schwemmer L, Hube-Magg C, Büscheck F, Höflmayer D, Tsourlakis M, Clauditz T, Luebke A, Simon R, Sauter G, Izbicki J, Schroeder C, Schlomm T, Huland H, Heinzer H, Haese A, Graefen M, Göbel C, Weidemann S, Lebok P, Dum D, Fraune C, Minner S, Meiners J
ONCOTARGET. 2019;10(67):7096-7111.

Improved risk stratification by circulating tumor cell counts in pancreatic cancer
Effenberger K, Schroeder C, Hanssen A, Wolter S, Eulenburg C, Tachezy M, Gebauer F, Izbicki J, Pantel K, Bockhorn M
CLIN CANCER RES. 2018;24(12):2844-2850.

Upregulation of centromere protein F is linked to aggressive prostate cancers
Göbel C, Özden C, Schroeder C, Hube-Magg C, Kluth M, Möller-Koop C, Neubauer E, Hinsch A, Jacobsen F, Simon R, Sauter G, Michl U, Pehrke D, Huland H, Graefen M, Schlomm T, Luebke A
CANCER MANAG RES. 2018;10:5491-5504.

PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer
Heinrich M, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A
BMC CANCER. 2018;18(1):612.

Immunohistochemically detected IDH1 mutation is rare and mostly heterogeneous in prostate cancer
Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz T, Krech T, Tsourlakis M, Schroeder C
WORLD J UROL. 2018;36(6):877-882.

High expression of class III β-tubulin in upper gastrointestinal cancer types
Höflmayer D, Öztürk E, Schroeder C, Hube-Magg C, Blessin N, Simon R, Lang D, Neubauer E, Göbel C, Heinrich M, Fraune C, Möller K, Armbrust M, Freytag M, Hinsch A, Lühr C, Noack M, Reiswich V, Weidemann S, Bockhorn M, Perez D, Izbicki J, Sauter G, Jacobsen F
ONCOL LETT. 2018;16(6):7139-7145.

EZH2 overexpression in head and neck cancer is related to lymph node metastasis
Nienstedt J, Schroeder C, Clauditz T, Simon R, Sauter G, Muenscher A, Blessmann M, Hanken H, Pflug C
J ORAL PATHOL MED. 2018;47(3):240-245.

Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer
Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Sauter G, Izbicki J, Clauditz T, Luebke A, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis M, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N
NEOPLASIA. 2017;19(9):707-715.

High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer
Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Möller-Koop C, Steurer S, Sauter G, Jacobsen F, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis M, Minner S, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Wilczak W
INT J MOL SCI. 2017;18(2):286.

THSD7A expression in human cancer
Stahl P, Hoxha E, Wiech T, Schröder C, Simon R, Stahl R
GENE CHROMOSOME CANC. 2017;56(4):314-327.

FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy
Tsourlakis M, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F
CARCINOGENESIS. 2017;38(12):1180-1187.

Upper Gastrointestinal Endoscopy prior to Bariatric Surgery-Mandatory or Expendable? An Analysis of 801 Cases
Wolter S, Duprée A, Miro J, Schroeder C, Jansen M, Schulze-Zur-Wiesch C, Groth S, Izbicki J, Mann O, Busch P
OBES SURG. 2017;27(8):1938-1943.

Disseminated tumor cells in pancreatic cancer-an independent prognosticator of disease progression and survival.
Harms-Effenberger K, Schröder C, Zu Eulenburg C, Reeh M, Tachezy M, Riethdorf S, Vashist Y, Izbicki J, Pantel K, Bockhorn M
INT J CANCER. 2012;131(4):475-483.

Letzte Aktualisierung aus dem FIS: 25.02.2020 - 00:40 Uhr